Subscribe To
QBIO / Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver cancer
QBIO News
By Proactive Investors
April 14, 2023
Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value
Q BioMed Inc. (OTCQB:QBIO) said it has received a patent in the US and a notice of allowance in Europe for the Uttroside B chemotherapeutic asset, more_horizontal
By Proactive Investors
February 10, 2023
Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B
Q BioMed Inc. (OTCQB:QBIO) has received a notice of an allowable patent from the US Patent Office related to its liver cancer treatment Uttroside B. T more_horizontal
By Proactive Investors
July 29, 2022
Q BioMed reports Strontium89 sales revenue surge in shareholder update
Q BioMed Inc said it has seen an uptick in sales revenue from Strontium89, the company's potential chemotherapeutic drug, in its recently reported qua more_horizontal
By Proactive Investors
July 26, 2022
Q BioMed says new publication shows superior safety and efficacy of Uttroside-B versus FDA approved drug Sorafenib
Q BioMed Inc has highlighted that its pre-clinical Uttroside-B chemotherapeutic to treat liver cancer has been found in a new study to show superior s more_horizontal
By Proactive Investors
May 6, 2022
Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets
Q BioMed Inc told investors that it had studiously avoided biotech single-asset risks by acquiring multiple assets over time, across a broad spectrum more_horizontal
By Proactive Investors
March 16, 2022
Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver cancer
Q BioMed Inc. (OTCQB:QBIO) has announced a new publication in the Frontiers of Oncology journal supporting the efficacy and further development of its more_horizontal
By Proactive Investors
February 14, 2022
Q BioMed outlines strategic direction and goals for 2022
Q BioMed Inc has outlined its strategic directions and goals for 2022 that call for increasing revenues as the biotech seeks to monetize its current p more_horizontal
By Proactive Investors
February 14, 2022
Q BioMed outlines strategic direction and goals for 2022
Q BioMed Inc has outlined its strategic directions and goals for 2022 that call for increasing revenues as the biotech seeks to monetize its current p more_horizontal
